Rituximab biosimilar (Hualan Biological Engineering)

利妥昔单抗生物类似药（华兰基因）

Report date: 2024/11/25 10:52:31

Base Information

Drug NameRituximab biosimilar (Hualan Biological Engineering)

Drug Alias Name重组抗淋巴细胞瘤(CD20)单抗(利妥昔单抗)（华兰基因工程）利妥昔单抗生物仿制药（华兰基因）WBP-263

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusNDA/BLA

Highest Status in ChinaNDA/BLA

Originator CompaniesHualan Ankang Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHualan Ankang Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeL01XC02